发明名称 |
CONTROLLED RELEASE FORMULATION OF DIVALPROEX SODIUM |
摘要 |
A controlled release tablet formulation which permits once daily dosing in t he treatment of epilepsy comprises from about 50 weight percent to about 55 weight percent of an active ingredient selected from the group consisting of valproic acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, and valpromide; from about 20 weight percent to about 40 weight percent hydroxypropyl methylcellulose; from about 5 weight percent to about 15 weight percent lactose, from about 4 weight percent to about 6 weig ht percent microcrystalline cellulose, and from about 1 weight percent to about 5 weight percent silicon dioxide having an average particle size ranging betwe en about 1 micron and about 10 microns; all weight percentages based upon the total weight of the tablet dosage form. Also disclosed are pre-tableting granular formulations, methods of making the granular formulations and tablets, and a method of treating epilepsy employing the controlled release tablet formulations of the invention.
|
申请公布号 |
CA2330480(A1) |
申请公布日期 |
2000.06.29 |
申请号 |
CA19992330480 |
申请日期 |
1999.12.09 |
申请人 |
ABBOTT LABORATORIES |
发明人 |
ENGH, KEVIN R.;POSKA, RICHARD P.;BOLLINGER, J. DANIEL;CHESKIN, HOWARD S.;QUI, YIHONG |
分类号 |
A61K9/26;A61K9/20;A61K9/22;A61K31/16;A61K31/19;A61K31/23;A61K47/02;A61K47/26;A61K47/38;A61P25/08;(IPC1-7):A61K9/22;A61K9/16 |
主分类号 |
A61K9/26 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|